Arcutis Biotherapeutics, Inc. ARQT
28.34 USD -0.04 (-0.14%)
Nov 12, 2026, 2:06 PM EST
27.95 Day range 28.91
19.30 52-week range 34.80
- YTD
- -2.41%
- 1 year
- +20.85%
News
defenseworld.net Arcutis Biotherapeutics (NASDAQ:ARQT) EVP Sells $1,372,800.00 in Stock Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT - Get Free Report) EVP Masaru Matsuda sold 40,000 shares of the stock in a transaction that occurred on Wednesday, November 4th. The shares were sold at an…- defenseworld.net Arcutis Biotherapeutics (NASDAQ:ARQT) EVP Sells $1,372,800.00 in Stock Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT - Get Free Report) EVP Masaru Matsuda sold 40,000 shares of the stock in a transaction that occurred on Wednesday, November 4th. The shares were sold at an…
globenewswire.com Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) WESTLAKE VILLAGE, Calif., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in…
benzinga.com TD Cowen Maintains Buy on Arcutis Biotherapeutics, Raises Price Target to $40 TD Cowen analyst Tyler Van Buren maintains Arcutis Biotherapeutics (NASDAQ:ARQT) with a Buy and raises the price target from $35 to $40.
benzinga.com Zillow Posts Downbeat Q3 Results, Joins HubSpot, Snap And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session U.S. stock futures were mixed as Zillow and several companies fell sharply premarket after weak results and lowered sales guidance.- benzinga.com Arcutis Biotherapeutics Initiates Enrollment In Its INTEGUMENT-3 Trial To Evaluate ZORYVE To Treat Atopic Dermatitis Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that the first…
globenewswire.com Arcutis Begins Enrolling Phase 3 Study Evaluating ZORYVE® (roflumilast) Cream 0.3% in Moderate to Severe Atopic Dermatitis New INTEGUMENT-3 study to evaluate efficacy, safety, and tolerability of investigational ZORYVE® cream 0.3% in individuals with moderate to severe atopic dermatitis Study aims to expand once-daily…
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session Gainers ADMA Biologics (NASDAQ:ADMA) shares rose 19.6% to $12.53 during Thursday's pre-market session. The market value of their outstanding shares is at $2.3 billion. As per the news, the Q3…
benzinga.com Why AppLovin Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket AppLovin surged 16.5% premarket after Q3 revenue and EPS beat estimates and Q4 guidance topped forecasts; MNTN plunged 42.3% on weak results.
benzinga.com Arcutis Biotherapeutics Announces $200M At-The-Market Common Stock Offering ARCUTIS BIOTHERAPEUTICS, INC.$200,000,000Common StockWe have entered into an amended and restated sales agreement, or the Sales Agreement, with TD Cowen, relating to shares of our common stock…
benzinga.com Arcutis Biotherapeutics Q3 2026 Earnings Call Transcript Arcutis Biotherapeutics (NASDAQ:ARQT) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session Gainers Revolution Medicines (NASDAQ:RVMD) stock rose 14.1% to $227.83 during Wednesday's after-market session. The market value of their outstanding shares is at $41.6 billion. As per the news, the…- benzinga.com Arcutis Biotherapeutics Q3 EPS $0.06 Misses $0.12 Estimate, Sales $143.919M Beat $142.592M Estimate Arcutis Biotherapeutics (NASDAQ:ARQT) reported quarterly earnings of $0.06 per share which missed the analyst consensus estimate of $0.12 by 50 percent. This is unchanged from the same period last…
benzinga.com Guggenheim Maintains Buy on Arcutis Biotherapeutics, Raises Price Target to $44 Guggenheim analyst Seamus Fernandez maintains Arcutis Biotherapeutics (NASDAQ:ARQT) with a Buy and raises the price target from $38 to $44.
benzinga.com Why Is Arcutis Biotherapeutics Stock Surging Thursday? Cantor Fitzgerald initiated Arcutis (ARQT) at Overweight with a $48 target, citing Zoryve's potential for $3.5B in peak sales.- benzinga.com Cantor Fitzgerald Initiates Coverage On Arcutis Biotherapeutics with Overweight Rating, Announces Price Target of $48 Cantor Fitzgerald analyst Steve Seedhouse initiates coverage on Arcutis Biotherapeutics (NASDAQ:ARQT) with a Overweight rating and announces Price Target of $48.
- benzinga.com Arcutis Presents ZORYVE Data At EADV Congress Presentation of data from the INTEGUMENT-INFANT trial of investigational ZORYVE cream 0.05% in infants ages 3 to <24 months, where treatment options remain limitedNew analyses from the ARRECTOR and…
benzinga.com Bloom Energy, Illumina, and Everpure Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400, and S&P SmallCap 600 https://www.spglobal.com/spdji/en//documents/indexnews/announcements/20260904-1484999/1484999_shuffle5461-sept2026.pdf
benzinga.com Arcutis Biotherapeutics’ Subsidiary Arcutis Canada Secures Health Canada Approval For Roflumilast Cream In Pediatric Atopic Dermatitis Patients Health Canada approval of new 0.05% cream formulation expands the ZORYVE portfolio to include a once-daily, steroid-free option for younger childrenThe 0.05% formulation was specifically selected for…- benzinga.com Morgan Stanley Maintains Overweight on Arcutis Biotherapeutics, Raises Price Target to $38 Morgan Stanley analyst Vikram Purohit maintains Arcutis Biotherapeutics (NASDAQ:ARQT) with a Overweight and raises the price target from $34 to $38.
- benzinga.com Guggenheim Maintains Buy on Arcutis Biotherapeutics, Raises Price Target to $38 Guggenheim analyst Seamus Fernandez maintains Arcutis Biotherapeutics (NASDAQ:ARQT) with a Buy and raises the price target from $35 to $38.
- benzinga.com Needham Maintains Buy on Arcutis Biotherapeutics, Raises Price Target to $40 Needham analyst Serge Belanger maintains Arcutis Biotherapeutics (NASDAQ:ARQT) with a Buy and raises the price target from $36 to $40.
- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session Gainers Creative Medical Tech (NASDAQ:CELZ) stock moved upwards by 31.4% to $0.88 during Wednesday's after-market session. The company's market cap stands at $4.2 million. Caris Life Sciences…
- benzinga.com Arcutis Biotherapeutics Q2 EPS $0.11 Beats $0.03 Estimate, Sales $129.861M Beat $118.852M Estimate Arcutis Biotherapeutics (NASDAQ:ARQT) reported quarterly earnings of $0.11 per share which beat the analyst consensus estimate of $0.03 by 266.67 percent. This is a 184.62 percent increase over…
- benzinga.com FDA Accepts Supplemental New Drug Application For Arcutis Biotherapeutics' ZORYVE Cream 0.05% FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of February 23, 2027Application supported by positive results from Phase 2 open-label INTEGUMENT-INFANT study and Phase 1…
- benzinga.com Reported Earlier, Arcutis Expands ZORYVE Label With FDA Approval For Once-Daily Steroid-Free Plaque Psoriasis Treatment In Young Children ZORYVE cream 0.3% is the first once-daily, non-steroidal therapy approved for children with plaque psoriasis as young as 2 years of ageZORYVE cream 0.3% is safe, effective, and well-tolerated for use…
benzinga.com UPDATE: Arcutis Highlights New Expert Guidance For Diagnosing And Managing Genital Psoriasis Across All Age Groups Expert recommendations focused on the diagnosis and management of genital psoriasis across age groups including pediatric, adult, and older populationsThis is the second published manuscript from the…- benzinga.com Needham Reiterates Buy on Arcutis Biotherapeutics, Maintains $36 Price Target Needham analyst Serge Belanger reiterates Arcutis Biotherapeutics (NASDAQ:ARQT) with a Buy and maintains $36 price target.
benzinga.com Earnings Scheduled For May 6, 2026 
benzinga.com Arcutis Biotherapeutics Q1 EPS $(0.09) Misses $(0.06) Estimate, Sales $105.398M Beat $101.261M Estimate Arcutis Biotherapeutics (NASDAQ:ARQT) reported quarterly losses of $(0.09) per share which missed the analyst consensus estimate of $(0.06) by 50 percent. This is a 55 percent increase over losses of…- benzinga.com Arcutis Biotherapeutics Announces Submission Of sNDA To FDA Seeking To Expand Indication For ZORYVE Cream 0.05% To Include Topical Treatment Of Atopic Dermatitis In Infants Down To 3 Months Submission supported by data from INTEGUMENT-INFANT Phase 2 open-label study in infants aged 3 months to less than 24 months with mild to moderate atopic dermatitisOnce-daily ZORYVE cream was well…
benzinga.com Arcutis Biotherapeutics Announces ZORYVE Cream Receives Strong Recommendation, With High Certainty Of Clinical Evidence, In AAD Clinical Practice Guidelines For Management Of Pediatric Atopic Dermatitis Strong recommendation with high certainty of clinical evidence underscores proven efficacy, safety, and tolerability of ZORYVE cream as a steroid-free topical phosphodiesterase type 4 (PDE4)…
benzinga.com Reported Saturday, Arcutis' Phase 2 INTEGUMENT-INFANT Trial Shows Zoryve Cream 0.05% Achieves 49% Clear Or Almost Clear Skin And 58.3% EASI-75 In Infants With Atopic Dermatitis Investigational ZORYVE® (roflumilast) cream 0.05% was well tolerated with safety findings consistent with prior pediatric experience in the INTEGUMENT programZORYVE cream improved signs and symptoms…- benzinga.com Arcutis Biotherapeutics To Present New Data From Its Clinical Development Program And Marketed ZORYVE Portfolio Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that it will present new…
- benzinga.com Arcutis Biotherapeutics Enrolls The First Participant In Phase 1a/1b Study (ARQ-234-131) To Evaluate Safety And Tolerability For Investigational Arq-234 In Healthy Volunteers And Adults With Moderate To Severe Atopic Dermatitis Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that the first…
- benzinga.com Mizuho Maintains Outperform on Arcutis Biotherapeutics, Lowers Price Target to $35 Mizuho analyst Uy Ear maintains Arcutis Biotherapeutics (NASDAQ:ARQT) with a Outperform and lowers the price target from $37 to $35.
- benzinga.com Guggenheim Maintains Buy on Arcutis Biotherapeutics, Raises Price Target to $35 Guggenheim analyst Seamus Fernandez maintains Arcutis Biotherapeutics (NASDAQ:ARQT) with a Buy and raises the price target from $34 to $35.
benzinga.com Forecasting The Future: 4 Analyst Projections For Arcutis Biotherapeutics - benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
- benzinga.com Earnings Scheduled For February 25, 2026
benzinga.com 10 Health Care Stocks With Whale Alerts In Today's Session - benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
benzinga.com Crude Oil Falls Over 2%; PayPal Shares Spike Higher 
benzinga.com Wayfair, Qorvo, Celestica, United Parcel Service, Regeneron Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday 
benzinga.com Earnings Scheduled For October 28, 2025 - benzinga.com Earnings Scheduled For August 6, 2025
- benzinga.com Earnings Scheduled For May 6, 2025
benzinga.com Celsius, Lucid And Signet Are Among Top 10 Mid-Cap Gainers Last Week (Mar 17-Mar 21): Are The Others In Your Portfolio? Top performers last week: DGNX (108.29%), NEXT (25.07%), CELH (21.60%), SIG (21.08%), NFE (20.63%), MRP (16.61%), ARQT (16.35%), LCID (15.79%), CPRX (15.27%), STNE (14.20%). Are they in your…- benzinga.com Earnings Scheduled For February 25, 2025
benzinga.com Why Sage Therapeutics Shares Are Trading Higher By Over 34%; Here Are 20 Stocks Moving Premarket